This small-cap Pharma Stock, engaged in manufacturing and marketing pharmaceutical formulations and APIs, serving regulated and emerging markets with a focus on quality, compliance, and innovation, is in focus after management expected 50% growth in revenue and 100% growth in net profit for FY26.
With a market capitalization of Rs. 2,609.86 crore, the shares of Senores Pharmaceuticals Limited closed at Rs. 566.70 per equity share, down nearly 1.26 percent from its previous day’s close price of Rs. 573.95.
Guidance: For FY26, Senores Pharmaceuticals has guided for strong growth, targeting at least 50 percent year-on-year revenue growth and aiming for 100 percent growth in profit after tax (PAT) compared to current levels. The company also expects to maintain a healthy EBITDA margin of around 25 percent, reflecting operational efficiency and improved profitability.
Capex: Senores Pharmaceuticals has planned a capex of Rs. 250 crores for FY26. The company is also preparing to invest in an injectable facility by the end of FY26. Additionally, a new greenfield site in India is being developed to support both semi-regulated and regulated markets. Production has begun at its API facility (100–120 MTPA) as of March 2025, with an FDA inspection targeted for Q2CY26.
Product Launches: Senores Pharmaceuticals will launch 31 ANDA and 23 CDMO/CMO products in regulated markets during FY26. Additionally, the company will begin phased commercialization of recently acquired ANDAs from Dr. Reddy’s and Breckenridge from Q3FY26.
Senores Pharmaceuticals registered 48 new products in Q4 FY25, taking the total to 285 as of March 2025. The company aims to reach over 650 registered products by FY27, highlighting its strong pipeline and focus on expanding its global presence through consistent product development and regulatory approvals.
Overview: Senores Pharmaceuticals Limited was founded in 2017 and is a rapidly growing pharmaceutical company headquartered in Ahmedabad, India. The company specializes in the development, manufacturing, and global distribution of affordable, high-quality complex generics and active pharmaceutical ingredients (APIs).
Global Presence: Senores Pharmaceuticals has a strong global presence, operating in 49 countries. The company has manufacturing and marketing operations across key regions, including the USA, India, Africa, the Middle East, CIS, Latin America, and others, supporting its international growth and broad market reach.
Manufacturing Facilities: Senores Pharmaceuticals operates 4 manufacturing facilities, which include 1 USFDA-approved formulation plant and 2 plants dedicated to APIs and intermediates. The company also runs 15 manufacturing lines specifically catering to emerging markets, showcasing its strong production capabilities and regulatory compliance for global supply.
Financial Highlights: Senores Pharmaceuticals Limited’s revenue has increased from Rs. 102 crore in Q4 FY24 to Rs. 114 crore in Q4 FY25, which is a growth of 11.76 percent. The net profit has also grown by 28.57 percent, from Rs. 14 crore in Q4 FY24 to Rs. 18 crore in Q4 FY25. Senores Pharmaceuticals Limited’s revenue and net profit have grown at a CAGR of 205.20 percent and 287.09 percent, respectively, over the last three years.
In terms of return ratios, the company’s ROCE and ROE stand at 11.4 percent and 11.8 percent, respectively. Senores Pharmaceuticals Limited has an earnings per share (EPS) of Rs. 12.7, and its debt-to-equity ratio is 0.40x.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma stock with 100% net profit growth guidance for FY26 to keep an eye on appeared first on Trade Brains.